Vistagen Therapeutics, Inc. 8-K

What Happened Vistagen Therapeutics, Inc. (VTGN) filed a Form 8-K disclosing that director Paul Edick resigned from the company's Board of Directors effective February 13, 2026. The filing was signed by President and CEO Shawn K. Singh and dated February 20, 2026.

Key Details

• Filing: Form 8-K under Item 5.02 (Departure of Directors or Certain Officers).
• Resignation effective date: February 13, 2026.
• Director who resigned: Paul Edick.
• Company response: Vistagen said it is actively seeking new candidates to fill the resulting Board vacancy.

Why It Matters A board resignation is a governance event investors watch because it changes board composition and could affect oversight of management and strategy. Vistagen has not named a replacement or given reasons for the resignation in the 8-K; the company’s active search for candidates indicates the vacancy will be addressed but no timeline was provided. Investors who track corporate governance or vote-related matters may want to monitor future disclosures for a new director appointment or any related governance updates.